IPO
Investment in Michigan Facility Targets Future Growth for High-Demand Natural Insecticide Technology
GAAP earnings per share (EPS) from continuing operations was a loss of $(0.69) for the third quarter and operating EPS1 was a loss of $(0.39) – both improved compared to prior year.
Further German cooperation with the Paracelsus Clinic in Zwickau and first NanoTherm treatment center outside of Germany opened at the Independent Public Clinical Hospital No. 4 (SPKS4) in Lublin, Poland
MorphoSys AG reported its financial results for the third quarter of 2019.
Esperion announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open..
BioVersys AG announced, US$ 3.94 million in non-dilutive funding from CARB-X, with the possibility of US$ 4.98 million more if certain project milestones are met.
Financing will support Sense’s development of instrument-free molecular diagnostics aimed at true point-of-care testing
Sense Biodetection Limited raises £12.3m to progress instrument-free molecular diagnostics
Initial focus on diagnosing infectious disease through development of machine-free, lab-quality, True Point-of-Care™ products
Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record Platform
PRESS RELEASES